HR and breast carcinoma: The phase III clinical trial (NCT01958021) and (NCT02278120) demonstrated that ribociclib and letrozole combination therapy can improve the progression-free survival (PFS) of postmenopausal and premenopausal women with HR+/HER2-negative breast cancer, respectively (29, 30).